Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business

Acquisition to include non-US rights to roflumilast and will be
accretive to 2016 earnings, contributing to AstraZeneca's return to
growth strategy

AstraZeneca today announced that it has entered into a definitive
agreement to acquire the core respiratory business of Takeda
Pharmaceutical Company Limited ("Takeda"). The deal will include the
expansion of rights to roflumilast (marketed as Daliresp in the US
and Daxas in other countries), the only approved oral PDE4 inhibitor
for the treatment of chronic obstructive pulmonary disease (COPD).

AstraZeneca has marketed Daliresp in the US since the acquisition of
the rights from Actavis in the first quarter of 2015. Full
acquisition of the global rights will support AstraZeneca's
respiratory franchise and complement the company's portfolio of
treatments for severe COPD. Recent data1 reinforce the benefit Daxas
brings to patients in reducing exacerbations as an add-on to dual and
free-triple2 inhaled combination therapies. The agreement will also
provide AstraZeneca with access to other marketed respiratory
medicines and early pipeline products.

Under the terms of the agreement, AstraZeneca will make a payment of
$575 million. Approximately 200 staff will transfer to AstraZeneca
upon completion.

Luke Miels, Executive Vice President Global Portfolio and Product
Strategy at AstraZeneca, said: "The agreement with Takeda complements
our respiratory business, one of our three main therapy areas,
supports our return to growth and will be immediately accretive to
earnings from 2016. Daxas in particular adds to our portfolio of
treatments for patients with severe COPD."

Annual global sales of the three core medicines acquired, excluding
any AstraZeneca sales of Daliresp in the US3, were $198 million for
the period ending in March 2015. The transaction will be accounted
for as a business combination and is expected to close during the
first quarter of 2016, subject to customary closing conditions. It is
expected to be immediately accretive to earnings from 2016. The
acquisition of global rights to Daliresp will also negate the
Company's existing royalty payments for the medicine in the US. Full
Year 2016 guidance is expected to be provided at Full Year 2015
results on 4 February 2016.

- ENDS -


1 Martinez FJ, Calverley PMA, Goehring U, et al. Effect of roflumilast
on exacerbations in patients with severe chronic obstructive
pulmonary disease uncontrolled by combination therapy (REACT): a
multicentre randomised controlled trial. The Lancet.

2 Inhaled corticosteroid/long-acting beta2-adrenergic agonist +
Long-acting muscarinic antagonist.

3 Annual global sales of Daxas, Alvesco (for asthma) and Omnaris (for
allergic rhinitis). AstraZeneca has marketed Daliresp in the US since
the acquisition of the rights from Actavis, which completed on 3
March 2015. This figure excludes any AstraZeneca sales of Daliresp in
the US.

About Daliresp/Daxas

Daliresp (roflumilast) is available in the US as a treatment indicated
to reduce the risk of COPD exacerbations in patients with severe COPD
associated with chronic bronchitis and a history of exacerbations.
Daliresp is not a bronchodilator and is not indicated for the relief
of acute bronchospasm.

Daxas (roflumilast) is available in Europe as a treatment indicated
for maintenance treatment of severe chronic obstructive pulmonary
disease (COPD) (FEV1 post-bronchodilator less than 50% predicted)
associated with chronic bronchitis in adult patients with a history
of frequent exacerbations as add on to bronchodilator treatment.

Daliresp/Daxas has a unique position in severe COPD as the only PDE4
inhibitor that reduces the rate of COPD exacerbations in a subset of
patients who still suffer from exacerbations despite maximum
bronchodilation up to 45.5%, depending on background therapy and
previous exacerbation pattern. Daliresp/Daxas has also been shown to
reduce hospitalisations due to severe exacerbations.1

About Takeda

Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global
company with its main focus on pharmaceuticals. As the largest
pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to strive towards better health for
people worldwide through leading innovation in medicine. Additional
information about Takeda is available on

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - respiratory, inflammation, autoimmune
disease (RIA), cardiovascular and metabolic disease (CVMD) and
oncology - as well as in infection and neuroscience. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information please visit:


Media Enquiries
Esra Erkal-Paler UK/Global +44 20 7604 8030
Neil Burrows UK/Global +44 20 7604 8032
Vanessa Rhodes UK/Global +44 20 7604 8037
Karen Birmingham UK/Global +44 20 7604 8120
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Enquiries
Thomas Kudsk Larsen Oncology +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44 7827 836825
Lindsey Trickett Oncology, ING +1 240 543 7970
Mitch Chan Oncology +1 240 477 3771
Dial / Toll-Free +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD -
Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.